Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis

Journal of Clinical Investigation

Volumn 103, Issue 7, 1999, Pages 1007-1013

  Rittner, Heike L ^a   Hafner, Verena ^a   Klimiuk, Piotr A ^a   Szweda, Luke I ^b   Goronzy, Jörg J ^a   Weyand, Cornelia M ^a  

^a MAYO CLINIC   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; ZOPOLRESTAT;

ANTIGEN RECOGNITION; APOPTOSIS; ARTICLE; DETOXIFICATION; GIANT CELL; HUMAN; HUMAN TISSUE; INFLAMMATORY INFILTRATE; LIPID PEROXIDATION; MONONUCLEAR CELL; OSMOLARITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; TEMPORAL ARTERY; VASCULITIS;

EID: 0032947546     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI4711     Document Type: Article

References (37)

1. Weyand, C.M., and Bartley, G.B. 1997. Giant cell arteritis: new concepts in pathogenesis and implications for management. Am. J. Ophthalmol. 123:392-395.
2. Hunder, G.G. 1997. Giant cell arteritis and polymyalgia rheumatica. Med. Clin. North Am. 81:195-219.
3. Weyand, C.M., and Goronzy, J.J. 1995. Giant cell arteritis as an antigen-driven disease. Rheum. Dis. Clin. North Am. 21:1027-1039.
4. Martinez-Taboada, V., Hunder, N.N., Hunder, G.G., Weyand, C.M., and Goronzy, J.J. 1996. Recognition of tissue residing antigen by T cells in vasculitic lesions of giant cell arteritis. J. Mol. Med. 74:695-703.
5. Wagner, A.D., Bjornsson, J., Bartley, G.B., Goronzy, J.J., and Weyand, C.M. 1996. Interferon-gamma-producing T cells in giant cell vasculitis represent a minority of tissue-infiltrating cells and are located distant from the site of pathology. Am. J. Pathol. 148:1925-1933.
6. Kaiser, M., Weyand, C.M., Bjornsson, J., and Goronzy, J.J. 1998. Platelet derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum. 41:623-633.
7. Weyand, C.M., Wagner, A.D., Bjornsson, J., and Goronzy, J.J. 1996. Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis. J. Clin. Invest. 98:1642-1649.
8. Sorbi, D., et al. 1996. Elevated levels of 92-kd type IV collagenase (matrix metalloproteinase 9) in giant cell arteritis. Arthritis Rheum. 39:1747-1753.
9. Rittner, H.L., et al. 1999. Tissue destructive macrophages in giant cell arteriris. Circ. Res. In press.
10. Poli, G., et al. 1985. Separation and characterization of the aldehydic products of lipid peroxidation stimulated by carbon tetrachloride or ADP-iron in isolated rat hepatocytes and rat liver microsomal suspensions. Biochem J. 227:629-638.
11. Uchida, K., Szweda, L.I., Chae, H.Z., and Stadtman, E.R. 1993. Immunochemical detection of 4-hydroxynonenal protein adducts in oxidized hepatocytes. Proc. Natl Acad. Sci. USA. 90:8742-8746.
12. Bohren, K.M., Bullock, B., Wermuth, B., and Gabbay, K.H. 1989. The aldoketo reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases. J. Biol. Chem. 264:9547-9551.
13. Flynn, T.G., and Green, N.C. 1993. The aldo-keto reductases: an overview. Adv. Exp. Med. Biol. 328:251-257.
14. Gabbay, K.H., Merola, L.O., and Field, R.A. 1966. Sorbitol pathway: presence in nerve and cord with substrate accumulation in diabetes. Science. 151:209-210.
15. Bhatnagar, A., Liu, S.Q., Das, B., Ansari, N.H., and Srivastava, S.K. 1990. Inhibition kinetics of human kidney aldose and aldehyde reductases by aldose reductase inhibitors. Biochem. Pharmacol. 39:1115-1124.
16. Brack, A., et al. 1997. Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras. J. Clin. Invest. 99:2842-2850.
17. Vinores, S.A., et al. 1988. Aldose reductase expression in human diabetic retina and retinal pigment epithelium. Diabetes. 37:1658-1664.
18. Brack, A., et al. 1997. Giant cell arteritis is a T cell dependent disease. Mol. Med. 3:530-543.
19. Grimshaw, C.E., and Mathur, E.J. 1989. Immunoquantitation of aldose reductase in human tissues. Anal. Biochem 176:66-71.
20. Kern, T.S., and Engerman, R.L. 1982. Immunohistochemical distribution of aldose reductase. Histochem. J. 14:507-515.
21. Beyer-Mears, A., Diecke, F.P., Mistry, K., and Cruz, E. 1997. Comparison of the effects of Zopolrestat and Sorbinil on lens myo-inositol influx. Pharmacology. 54:76-83.
22. Esterbauer, H. 1993. Cytotoxicity and genotoxicity of lipid-oxidation products. Am J. Clin. Nutr. 57:779S-785S.
23. Bohren, K.M., Grimshaw, C.E., and Gabbay, K.H. 1992. Catalytic effectiveness of human aldose reductase. Critical role of C-terminal domain. J. Biol. Chem. 267:20965-20970.
24. Robinson, B., Hunsaker, L.A., Stangebye, L.A., and Vander, J.D. 1993. Aldose and aldehyde reductases from human kidney cortex and medulla. Biochim. Biophys. Acta. 1203:260-266.
25. Ruepp, B., Bohren, K.M., and Gabbay, K.H. 1996. Characterization of the osmotic response element of the human aldose reductase gene promoter. Proc. Natl. Acad. Sci. USA. 93:8624-8629.
26. Wang, K., Bohren, K.M., and Gabbay, K.H. 1993. Characterization of the human aldose reductase gene promoter. J. Biol. Chem. 268:16052-16058.
27. Gabbay, K.H., and O'Sullivan, J.B. 1968. The sorbitol pathway. Enzyme localization and content in normal and diabetic nerve and cord. Diabetes. 17:239-243.
28. Gabbay, K.H., and Cathcart, E.S. 1974. Purification and immunologic identification of aldose reductases. Diabetes. 23:460-468.
29. Tomlinson, D.R. 1993. Aldose reductase inhibitors and the complications of diabetes mellitus. Diabet. Med. 10:214-230.
30. Pfeifer, M.A., Schumer, M.P., and Gelber, D.A. 1997. Aldose reductase inhibitors: the end of an era or the need for different trial designs? Diabetes. 46(Suppl.2):S82-S89.
31. Srivastava, S., Chandra, A., Bhatnagar, A., Srivastava, S.K., and Ansari, N.H. 1995. Lipid peroxidation product, 4-hydroxynonenal and its conjugate with GSH are excellent substrates of bovine lens aldose reductase. Biochem. Biophys. Res. Commun. 217:741-746.
32. Vander, J.D., Torres, J.E., Hunsaker, L.A., Deck, L.M., and Royer, R.E. 1997. Physiological substrates of human aldose and aldehyde reductases. Adv. Exp. Med. Biol. 414:491-497.
33. Vander, J.D., et al. 1995. Substrate specificity of human aldose reductase: identification of 4-hydroxynonenal as an endogenous substrate. Biochim. Biophys. Acta. 1249:117-126.
34. Spycher, S., Tabataba-Vakili, S., O'Donnell, V.B., Palomba, L., and Azzi, A. 1996. 4-hydroxy-2,3-trans-nonenal induces transcription and expression of aldose reductase. Biochem. Biophys. Res. Commun. 226:512-516.
35. Nathan, C.F. 1982. Secretion of oxygen intermediates: role in effector functions of activated macrophages. Fed. Proc. 41:2206-2211.
36. Esterbauer, H., Schaur, R.J., and Zollner, H. 1991. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11:81-128.
37. Montgomery, J.A., Jette, M., Huot, S., and Des, R.C. 1993. Acyloin production from aldehydes in the perfused rat heart: the potential role of pyruvate dehydrogenase. Biochem. J. 294:727-733.